Cg Oncology Inc Dossier
Qualitative Analysis
Business overview
CG Oncology, Inc. (formerly Cold Genesys, Inc.) is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative, bladder-sparing therapeutics for patients afflicted with urologic cancers, specifically bladder cancer. The company's lead product candidate, cretostimogene grenadenorepvec (cretostimogene), is an investigational, targeted oncolytic immunotherapy delivered intravesically. Cretostimogene is designed to selectively replicate in tumor cells and express granulocyte-macrophage colony-stimulating factor (GM-CSF), triggering a systemic anti-tumor immune response. The candidate is currently being evaluated in late-stage clinical trials, including the Phase 3 BOND-003 trial for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) and the Phase 3 PIVOT-006 trial as an adjuvant monotherapy for intermediate-risk NMIBC.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out commercial capabilities, establishing seamless product distribution networks, and setting up patient support systems to prepare for the potential commercial launch of cretostimogene grenadenorepvec.
Expected impact: Ensures rapid market penetration and efficient delivery of cretostimogene to patients and healthcare providers upon regulatory approval.
Proactively expanding manufacturing capacity and ensuring readiness for FDA pre-approval inspections. The current manufacturing process is designed to support commercial launch with a capacity of up to 50,000 vials annually.
Expected impact: Secures a sustainable, long-term commercial supply chain and mitigates regulatory risks associated with manufacturing quality.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Kissei exclusive rights to develop and commercialize cretostimogene in 20 Asian countries (including Japan, South Korea, and Taiwan, but excluding China), leveraging Kissei's strong regional urology expertise.
Terms: Kissei paid a $10.0 million upfront licensing fee and made a $30.0 million equity investment. Kissei is obligated to pay up to $33.0 million in development milestones, up to $67.0 million in commercial milestones, and royalties on net sales.
Grants Lepu an exclusive license to develop, manufacture, and commercialize cretostimogene in China, Hong Kong, Macau, and Taiwan.
Terms: Lepu paid a $4.5 million upfront payment and is obligated to pay up to $2.5 million in regulatory milestones, up to $57.5 million in commercial milestones, and high single-digit royalties on net sales.
Evaluating the safety and efficacy of cretostimogene in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with BCG-unresponsive NMIBC.
Terms: Clinical collaboration where Merck provides KEYTRUDA for the clinical trials.